Janessen has announced its drug BALVERSA or erdafitinib has received accelerated approval from the FDA “for the treatment of adults with locally advanced or metastatic urothelial carcinoma.”
Stephanie Chisolm, PhD, BCAN’s Director of Education and Research said, “This new treatment option is wonderful news for patients with metastatic bladder cancer. We appreciate industry focusing on treatments as new options are so badly needed. Let’s hope that more treatments that are in the pipeline will be approved for safe use soon.”
Read the press release here.